recurrence rates of up to 30%. Systemic therapy for advanced/recurrent EC is the cornerstone of treatment. This review discusses evidence-based therapeutic options for advanced/recurrent EC and reviews ongoing investigational therapies that may impact the
Search Results
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer
Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker
Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update
Diane L. Reidy-Lagunes
, liver-directed therapies, and systemic therapies. Cytotoxic therapies, such as temozolomide, fluorouracil, oxaliplatin, and streptozocin-based chemotherapy regimens, are active against some pancNETs, and can play a role in the palliation of patients with
Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
participating institution. For the purposes of this analysis, patients who received intraperitoneal chemotherapy in the first-line setting or who never received systemic therapy were excluded. The database was used to extract information regarding patient
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Featured Updates to the NCCN Guidelines
Neha Mehta-Shah, Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar, and Youn H. Kim
Cutaneous Lymphomas. Although this article predominantly discusses the role of systemic therapy, skin-directed therapies (eg, topical therapy, phototherapy, involved-site radiation therapy [RT], total skin electron-beam therapy [TSEBT]) also have an
Renal Cell Cancer: A Shift in Approaches for Treatment of Advanced Disease in the United States
Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff
RCC in community practice were examined, focusing on systemic therapy. Patients and Methods Data Source and Study Sample NCI Patterns of Care Data: The NCI SEER program collects information on all cancer diagnoses in defined geographic
Major Changes in Systemic Therapy for Advanced Melanoma
John A. Thompson
suggest the emergence of a plateau with Figure 1. NCCN recommendations for metastatic or unresectable melanoma: first-line systemic therapy. combination therapy. However, he added, a common side effect (noted in approximately 55% of patients
Machine Learning–Based Early Warning Systems for Acute Care Utilization During Systemic Therapy for Cancer
Robert C. Grant, Jiang Chen He, Ferhana Khan, Ning Liu, Sho Podolsky, Yosuf Kaliwal, Melanie Powis, Faiyaz Notta, Kelvin K.W. Chan, Marzyeh Ghassemi, Steven Gallinger, and Monika K. Krzyzanowska
–based early warning system to quantify the risk of ACU within 30 days after each systemic therapy treatment. A recent study developed a predictive model for ACU risk after treatment initiation using data from a comprehensive cancer center and found that
Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons
Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo
. For patients with BCLC stage C HCC, defined by macrovascular invasion and/or distant metastases, systemic therapy is the historical standard of care. However, for liver-confined BCLC stage C disease or limited extrahepatic spread, LRT can be effective
Single-Arm Longitudinal Study to Evaluate a Decision Aid for Women Offered Neoadjuvant Systemic Therapy for Operable Breast Cancer
Nicholas Zdenkowski, Phyllis Butow, Andrew Spillane, Charles Douglas, Kylie Snook, Mark Jones, Christopher Oldmeadow, Sheryl Fewster, Corinna Beckmore, Frances M. Boyle, and for the Australia and New Zealand Breast Cancer Trials Group
For women with large or highly proliferative operable breast cancer, the decision about whether to receive neoadjuvant systemic therapy (NAST) is guided by preferences that may lead to individual patients with similar clinical circumstances choosing
Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options
Presented by: Margaret A. Tempero
be the most common cause of cancer-related death by 2040. 1 , 2 To address the unmet needs and clinical challenges faced by this patient population, Dr. Tempero presented an update on systemic therapy options and relevant changes to the NCCN
